abstract |
The present invention consists of a pharmaceutical suspension formulation comprising, a particle formulation comprising, about 25 wt% to about 80 wt% drug, wherein the drug is a protein; and about 75 wt% to about 20 wt% of one or more additional component, wherein the ratio of drug:additional component is between about 1:1 to about 5:1.; and a non-aqueous, single-phase suspension vehicle comprising one or more polymer and one or more solvent; wherein the suspension vehicle exhibits viscous fluid characteristics, and the particle formulation is homogeneously dispersed in the vehicle. |